What is the difference between ACP-105 and LGD-3303?

ACP-105: ACP-105 is a non-peptide nonsteroidal selective androgen receptor modulator (SARM) of the azabicyclooctane chemotype, structurally related to AC-262536 and RAD140. It acts as a partial agonist at the ... LGD-3303: LGD-3303 is a non-peptide small molecule belonging to the pyrrolo[3,2-f]quinolinone class of selective androgen receptor modulators (SARMs). It has never been approved by the FDA or any regulatory age...

What does the research say about ACP-105 vs LGD-3303?

ACP-105: No human data exist for ACP-105. In castrated male rats, 2-week oral dosing improved anabolic parameters consistent with tissue-selective partial AR agonism, suppressed the LH surge, and produced levator ani muscle anabolic effects. In female mice (whole-body irradiated and sham-irradiated), ACP-105 preserved rotorod sensorimotor performance impair… LGD-3303: No human data exist for LGD-3303. No completed or registered clinical trials were found on ClinicalTrials.gov, and no PubMed record of a Phase 1 or later human trial exists. In castrated Sprague-Dawley rats, LGD-3303 showed potent anabolic (levator ani muscle) agonist activity but only partial agonist activity on androgenic tissues (ventral prostat…

ACP-105 vs LGD-3303

Q: Can you stack ACP-105 and LGD-3303?

ACP-105 (performance) and LGD-3303 (performance) are in the same category and may have overlapping mechanisms — researchers should review both profiles carefully before combining. Consult a licensed provider before combining any compounds.

Head-to-head comparison of ACP-105 and LGD-3303 — mechanism, side effects, legal status, and pricing.

ACP-105

ACP-105 is a non-peptide nonsteroidal selective androgen receptor modulator (SARM) of the azabicyclooctane chemotype, structurally related to AC-262536 and RAD140. It acts as a partial agonist at the androgen receptor with tissue-selective anabolic effects demonstrated in preclinical models. ACP-105 is not an approved drug in any jurisdiction and has never entered human clinical trials. SARMs as a class are prohibited at all times under WADA Prohibited List S1.2 'Other Anabolic Agents'; ACP-105 falls under this class-wide ban and has been the subject of equine anti-doping metabolite-detection research.

Profile Prices Testing

LGD-3303

LGD-3303 is a non-peptide small molecule belonging to the pyrrolo[3,2-f]quinolinone class of selective androgen receptor modulators (SARMs). It has never been approved by the FDA or any regulatory agency for human use, and no human clinical trials have been conducted or registered. LGD-3303 is prohibited under WADA's S1.2 category (Other Anabolic Agents), which covers all SARMs as a class. All available data are preclinical, derived from in vitro AR binding assays and in vivo studies in castrated rats and horses.

Profile Prices Testing

ACP-105

LGD-3303

Category

Performance

Legal Status

Research Only

Mechanism

ACP-105 is a nonsteroidal partial agonist at the androgen receptor (AR), discovered via receptor selection and amplification (R-SAT) high-throughput screening. It exhibits partial agonist activity relative to testosterone with tissue-selective anabolic effects, demonstrating potent and selective AR agonism in cell-based assays. No human receptor-binding or clinical pharmacology data exist; all mechanistic characterization is derived from in vitro assays and rodent models.

LGD-3303 is a nonsteroidal androgen receptor (AR) agonist. In castrated rat studies (Vajda et al. 2009, PMID 19017848), it bound and activated the AR to drive potent anabolic activity in levator ani muscle while acting only as a partial agonist in androgenic tissues (preputial gland, ventral prostate), never stimulating ventral prostate above intact-animal levels despite rising plasma concentrations. Tissue-selective activity persisted regardless of oral versus continuous-infusion dosing and despite higher local drug concentrations in prostate than in muscle, indicating the selectivity arises from altered molecular interaction at the AR itself rather than from differences in pharmacokinetic exposure or tissue distribution.

Side Effects

No human safety data exist
No validated human dose or GLP toxicology package publicly available
Prohibited under WADA S1.2 (SARMs class-wide ban)
Gray-market products may be mislabeled for identity/quantity (class-level SARM finding)

Where Researchers Are Buying

Live · updated daily

COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower

ACP-105

Best $/mg

$0.082/mg

Kimera ChemsC

1 trusted vendor listing

Compare all 1 vendor

LGD-3303

Best $/mg

$0.082/mg

Kimera ChemsC

1 trusted vendor listing

Compare all 1 vendor

Lab Verification

COA corpus from Disclosed Labs — independently tested batches only.

ACP-105

COAs

99.3%

Avg purity

Labs

Full testing data

LGD-3303

COAs

99.0%

Avg purity

Labs

Full testing data

ACP-105 Research Summary

No human data exist for ACP-105. In castrated male rats, 2-week oral dosing improved anabolic parameters consistent with tissue-selective partial AR agonism, suppressed the LH surge, and produced levator ani muscle anabolic effects. In female mice (whole-body irradiated and sham-irradiated), ACP-105 preserved rotorod sensorimotor performance impaired by radiation and enhanced cued fear conditioning while reducing MAP-2 immunoreactivity in sensorimotor cortex. In male gonadectomized 3xTg-AD Alzheimer's-model mice, ACP-105 alone reduced anxiety-like behavior; combined with the ER-beta agonist AC-186, it improved cognition (Morris water maze), increased amyloid-beta-degrading enzymes (neprilysin, IDE), and decreased brain amyloid-beta versus vehicle. Equine in vitro liver microsome studies identified twelve Phase I metabolites for doping-control detection purposes.

Key references

LGD-3303 Research Summary

No human data exist for LGD-3303. No completed or registered clinical trials were found on ClinicalTrials.gov, and no PubMed record of a Phase 1 or later human trial exists. In castrated Sprague-Dawley rats, LGD-3303 showed potent anabolic (levator ani muscle) agonist activity but only partial agonist activity on androgenic tissues (ventral prostate, preputial gland); tissue selectivity was maintained across both oral dosing and continuous infusion despite very different plasma exposure-time profiles (Vajda et al. 2009, PMID 19017848). In horses dosed orally at 0.05 mg/kg, eight metabolites (including hydroxylated and carboxylated forms with glucuronic acid conjugates) were tentatively identified in plasma and urine for doping-control purposes, with a monohydroxylated metabolite identified as the most sensitive analytical marker (Nilsson Broberg, Knych, Bondesson et al. 2023, PMID 37224728).

Can you stack ACP-105 and LGD-3303?

ACP-105 and LGD-3303 are both in the Performance category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.

Other comparisons

LGD-3303 vs RAD-140 ACP-105 vs RAD-140 LGD-3303 vs Ligandrol (LGD-4033)ACP-105 vs Ligandrol (LGD-4033)AC-262536 vs LGD-3303 LGD-3303 vs YK-11 GSK-2881078 vs LGD-3303 AC-262536 vs ACP-105

This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.